So it has been some time after I gambled 100 unit of MNKD at $0.65 per share and I earned a few dollars for that after I sell at at $0.93. Now I fully regretted that I sold the shares, it's $1.33 today! I've blogged about it previously: here.
Well, ever since I discover this company, I always wonder why Sanofi suddenly terminates the contract for such a revolutionary new drug. I do have plan to re-invest (with larger investment capital) into MNKD. Since I planned to invest larger, I did some study on it's financial reports. The result, it isn't pretty at all!
So MNKD was a pure R&D company who had spend over 10 years to come out with Afrezza and when they finally get the FDA approval and a deal with Sanofi, they expect to start earning profit from the sale. Unfortunately, Sanofi changed their mind and canceled the contract. Without any backup plan, and with the sudden left of the company founder Alfred Mann, the company is now lead by a not so competent CEO Matt, with very little cash left and uncertainties kicks in.
This company is in deep deep trouble!
Meyer Rothschild: "Buy when there is blood on the streets."
So now should be a great time to buy this company since I believe in it's product. But wait! Why Sanofi suddenly canceled the deal if it's such a great thing? There are many conspiracy theories and rumors among the investors and traders speculating about the real reason behind the cancellation, here are some of them:
1. Official Reason: Weak Sales
This is the official reason given by Sanofi. They claimed that they had put the best effort and the sales are still weak. Well, I doubt that it's real. I believe that the reason for weak sale is because it's still new and it's not well marketed. I haven't even heard of such product until I discover this company share price turned penny.
2. Change of Sanofi's CEO
So Chris Viehbacher has been fired by Sanofi's BoD, the new CEO Olivier Brandicourt leadership style is totally different! Some said that Brandicourt view Afrezza as a potential treat to they company's core product and should not be supported by the company. Therefore, Sanofi made a decision to cancel the deal.
3. Fear of Recall
Sanofi earnings was deeply affected by the recent recall of their Auvi-Q product. Which is the main trigger for Brandicourt to cancel the deal in fear of any un-foreseen problem with Afrezza. His fear is almost Luddite! I would say, if this is true, this almost an insult to FDA which had rejected and delayed their approval for Afrezza previously to ensure its safety. FDA have been working on it since 2010! Furthermore, Auvi-Q's failure is a mechanical failure, it has nothing to do with Afrezza.
Kiasi Is My Culture!
Because I'm kinda worried about the point number 3, I did some homework reading on Fumaryl Diketopiperazine (FDKP). Just copy and paste the name and search it on Google, plenty of research papers available. From the ones by MannKind, also with those from independent scholars. I think it is a new use of this particle, but it is pretty convincing that there won't be any significant side effect in short to medium term.
It is not just Afrezza
The key value of MNKD is not just Afrezza. Technosphere is the key! Many other drugs can be delivered with this technology. It is the key to open up new medication delivery method. Therefore, to sell Afrezza is just a short term plan to get the company out of the financial trouble. The R&D team still have this fancy TS toy to play with and make magic. I'm pretty convinced that this company can grow big.
I have position in this company! You do your own evaluation, I didn't ask you to buy or sell MNKD. It's up to you, you gotta do your own homework!